

July 9, 2020



SINTX Technologies Announces Closing of \$9.7 Million Registered Direct Offerings and Provides Business Update

SALT LAKE CITY, UT, July 09, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications announced the closing of its previously announced registered direct offerings which resulted in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately \$9,700,000 priced at-the-market under Nasdaq rules.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-230492) previously filed and declared effective by the Securities and Exchange Commission (SEC) on April 5, 2019. The offering of the shares of common stock was made by means of prospectus supplements that were filed with the SEC and form a part of the registration statement.

Maxim Group LLC acted as the sole placement agent for the offering. SINTX intends to use the net proceeds from the offerings for general working capital and general corporate purposes.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock was filed by SINTX with the SEC. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.

Update on Common Shares Outstanding

A summary of the Company's Capitalization Table as of June 30, 2020, is shown below.

Warrants Outstanding	1,147,140
Options Outstanding (as of December 31, 2019)	377
Shares Available under 2017 Equity Incentive Plan	2,520
Total Potentially Dilutive Securities	1,150,037
Common Shares Outstanding (as of June 30, 2020)	19,430,913

Series B Outstanding (as converted)*	93,560
Series C Outstanding (as converted)**	35,778
Total Shares & Potentially Dilutive Securities	20,710,288

Total Debt Outstanding \$ -

*126 Series B outstanding. Assuming conversion rate of 742.54:1.

**53 Series C outstanding. Assuming conversion rate of 675.05:1.

Comment on Preliminary Proxy Statement

The Company filed its preliminary proxy statement on June 26, 2020 for the annual shareholder meeting scheduled for August 13, 2020. Among the proposals is one to approve changing the Company's domicile from the State of Delaware to the State of Nevada. The Company has extensively researched this proposed change and has determined that it will not negatively impact the Company or its shareholders. The Company expects to see a significant reduction in franchise tax from this change and those savings will be invested back into Company operations.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things, that future studies may not confirm the antiviral properties of silicon nitride; that application of silicon nitride to products may not result in products with antiviral properties; uncertainties inherent in research and development, including the cost and time required advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX's other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Contact:
SINTX Technologies

801.839.3502

IR@sintx.com



Source: SINTX Technologies, Inc.